# Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients

> **NCT02420223** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Propranolol

## Key facts

- **NCT ID:** NCT02420223
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-17
- **Primary completion:** 2018-07
- **Final completion:** 2020-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420223, "Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02420223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*